SELLAS Triples as Cancer Vaccine Cuts Death Risk 41% in Phase 3 Leukemia Trial
SLS has more than doubled off its 52-week low of $1.39 on elevated volume (9.4× avg).
Summary
The pivotal Phase 3 REGAL trial of galinpepimut-S met its primary overall survival endpoint in second-remission AML, cutting death risk 41% (hazard ratio 0.59, p=0.035). Median overall survival was 24.0 months on GPS versus 14.7 months for best available treatment, with no new safety signals. The stock tripled to a 52-week high of $21.14 on 57.6 million shares versus a 6.9 million average. This follows the October 28 announcement that the trial hit its pre-specified 80th death event, which triggered this analysis. The company now plans to meet the FDA on an accelerated filing strategy and submit a BLA in the first half of 2027.
At the time of this announcement, SLS was trading at $20.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $1.39 to $24.89. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.